Grifols (GRFS) Non-Current Deferred Tax Liability (2009 - 2025)
Grifols (GRFS) posted Non-Current Deferred Tax Liability of $1.0 billion for Q4 2025, down 7.32% quarter-over-quarter from $1.1 billion in Q4 2024, and down 7.32% year-on-year from $1.1 billion in Q4 2024.
Grifols (GRFS) Non-Current Deferred Tax Liability (2009 - 2025) Analysis & Trends
Grifols (GRFS) has reported Non-Current Deferred Tax Liability for 16 consecutive years, with $1.0 billion the latest figure, recorded in Q4 2025.
- Non-Current Deferred Tax Liability for Q4 2025 came in at $1.0 billion, down 7.32% year-over-year; the trailing twelve-month figure through Dec 2025 was $1.0 billion (down 7.32% YoY), and the FY2025 annual result was $1.0 billion, down 7.32% from the prior year.
- Non-Current Deferred Tax Liability was $1.0 billion for Q4 2025 at Grifols, down from $1.1 billion in the prior quarter.
- Over five years, Non-Current Deferred Tax Liability peaked at $1.1 billion in Q4 2024 and troughed at $725.3 million in Q4 2021.
- Average Non-Current Deferred Tax Liability over 5 years is $985.7 million, with a median of $1.1 billion recorded in 2022.
- Year-over-year, Non-Current Deferred Tax Liability surged 45.57% in 2022 and dropped 7.32% in 2025.
- Over 5 years, Non-Current Deferred Tax Liability stood at $725.3 million in 2021, then surged by 45.57% to $1.1 billion in 2022, then grew by 0.75% to $1.1 billion in 2023, then increased by 1.67% to $1.1 billion in 2024, then decreased by 7.32% to $1.0 billion in 2025.
- Per Business Quant data, the three most recent Non-Current Deferred Tax Liability figures were $1.0 billion in Q4 2025, $1.1 billion in Q4 2024, and $1.1 billion in Q4 2023.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Eli Lilly | 1,066.16 Bn | 1,060.88 Bn | 16.22 Bn |
| 2 | Johnson & Johnson | 611.69 Bn | 589.64 Bn | 15.96 Bn |
| 3 | AbbVie | 444.34 Bn | 434.99 Bn | 10.78 Bn |
| 4 | Astrazeneca | 284.94 Bn | 277.05 Bn | 12.61 Bn |
| 5 | Merck | 224.23 Bn | 218.58 Bn | 12.09 Bn |
| 6 | Amgen | 195.12 Bn | 183.08 Bn | 5.87 Bn |
| 7 | Gilead Sciences | 156.45 Bn | 148.73 Bn | 5.52 Bn |
| 8 | Pfizer | 136.01 Bn | 123.24 Bn | -1.21 Bn |
| 9 | Novartis Ag | 113.45 Bn | 113.67 Bn | - |
| 10 | Grifols | - | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | 1.00 Bn |
| Dec 31, 2025 | 1.00 Bn |
| Dec 31, 2024 | 1.08 Bn |
| Dec 31, 2024 | 1.08 Bn |
| Dec 31, 2023 | 1.06 Bn |
| Dec 31, 2023 | 1.06 Bn |
| Dec 31, 2022 | 1.06 Bn |
| Dec 31, 2022 | 1.06 Bn |
| Dec 31, 2021 | 725.26 Mn |
| Dec 31, 2021 | 725.26 Mn |
| Dec 31, 2020 | 663.88 Mn |
| Dec 31, 2020 | 663.88 Mn |
| Dec 31, 2019 | 377.23 Mn |
| Dec 31, 2019 | 377.23 Mn |
| Dec 31, 2018 | 333.13 Mn |
| Dec 31, 2018 | 333.13 Mn |
| Jun 30, 2018 | 470.02 Mn |
| Jun 30, 2018 | 470.02 Mn |
| Dec 31, 2017 | 457.92 Mn |
| Dec 31, 2017 | 457.92 Mn |